Detalhe da pesquisa
1.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081335
2.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
3.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
4.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
5.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
6.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature
; 586(7830): 578-582, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731258
7.
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
Lancet
; 403(10436): 1554-1562, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555928
8.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
9.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
10.
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Lancet
; 397(10287): 1809-1818, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33964223
11.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
12.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
13.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
14.
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature
; 590(7844): E24, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469217
15.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
16.
Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation.
Proc Natl Acad Sci U S A
; 113(22): E3101-10, 2016 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27185949
17.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Nat Med
; 29(1): 147-157, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36228659
18.
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.
JCI Insight
; 7(6)2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192547
19.
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Front Immunol
; 13: 795463, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197971
20.
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine
; 85: 104298, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229342